ED, Decision Science Product Lead - Neuromuscular

Summary

This role can be located in East Hanover, NJ or Cambridge, MA.

The Insights & Analytics (I&A) team is dedicated to enabling improved decision making at Novartis by leveraging data and advanced analytics capabilities to generate actionable insights that drive business growth. We collaborate closely with the US business, bringing insights and challenging ideas to empower smarter, data-driven decision‑making. Reporting into the VP, TA and Launch Illuminator, this role is crucial in enabling proactive and integrated insight‑driven decision making for the brand, addressing business problems, shaping strategy and implementing decision science through I&A capabilities.

The Portfolio Illuminator is a strategic leader responsible for transforming complex data into actionable insights that drive brand success for a portfolio of products. This role is pivotal in integrating and synthesizing information from diverse sources to provide comprehensive, actionable answers that align with each brand’s strategic imperatives. By supporting the generation and analysis of insights throughout each product’s lifecycle as the connector between the I&A and several product teams, the individual ensures continuous insight‑generation and strategic alignment, fostering innovation and informed decision‑making.

Leading a team of high‑performing I&A PODs at the product level, this role is instrumental in shaping the brand’s strategic direction, ensuring that insights are effectively leveraged to achieve business goals. In addition to driving a brand’s success, the ED, Portfolio Illuminator will also be responsible for providing I&A leadership on multiple key, complex above‑brand strategic initiatives to build common capabilities which all brands in the portfolio can leverage.

The first set of above‑brand strategic initiatives will focus on building rare disease capabilities that will be leveraged across the portfolio and require significant cross‑I&A collaboration as the above‑brand capability build will involve every I&A pillar. Managing through the complexity of delivering above‑brand capabilities while still meeting the needs of individual brands in the portfolio will require strong leadership, cross‑functional collaboration and business judgment to navigate the ambiguity and deliver results.

As part of this the ED, Portfolio Illuminator will also sit on Therapeutic Area Alignment Forum (TAAF) sub‑committees and/or work streams which oversee the above‑brand strategic initiatives, and will exercise strong influencing skills to maintain alignment across multiple leadership bodies including the I&A LT to ensure Portfolio‑level direction is consistent with the direction of the overall US business. At the portfolio level, the ED, Portfolio Illuminator will be responsible for driving portfolio strategies, working with the TAAF sub‑committee to identify needs for additional above‑brand strategic initiatives, and collectively managing the brands to ensure delivery of key metrics at the portfolio level.

This will require working closely with multiple Launch Working Groups or Integrated Product Strategy Teams and bringing strategic acumen to focus on the key portfolio‑level insights with the GM organization and TAAF sub‑committee to deliver on the year’s objectives, as well as dynamic I&A resource prioritization and realignment within the portfolio working with each I&A Pillar. At the product level, the ED, Portfolio Illuminator will be responsible for directly leading one of the brands in the portfolio with highest strategic importance as the brand’s illuminator, and thus also leading the I&A brand POD.

This includes driving towards key brand deliverables such as the Integrated Product Strategy, Launch Readiness Reviews, Post Launch Reviews, and Monthly Business Reviews. Leading the I&A POD, the ED Portfolio Illuminator will work with the POD and IPST to collectively generate hypothesis and deliver actionable integrated insights which materially move brand performance. This also includes understanding key differences associated with new, advanced modalities including gene therapies, siRNA’s, associated…